TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). TearLab Research, Inc., its wholly owned subsidiary, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company's business. Its TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. In March 2014, the Company acquired assets of the OcuHub business unit from AOAExcel, Inc.